Novartis starts RELAXin as novel heart failure drug shows Phase III promise
This article was originally published in Scrip
Novartis is off to talk to regulators about approving its novel investigational treatment for acute heart failure, serelaxin, on the basis of a single Phase III study after top-line data showed it met one of its two primary endpoints measuring dyspnoea, with the added bonus of reducing all-cause mortality at six months, a secondary endpoint.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.